According to a recent report from Reuters, the Food and Drug Administration (FDA) has accepted NEVCORE Innovations' application for premarket tobacco product approval (PMTA) for its oral nicotine pouch brand, CLEW.
CLEW nicotine pouches come in flavors such as mint, fruit, and tobacco, with nicotine concentrations ranging from 3mg to 20mg.
The company's founder and chairman, Mr. Nutesh Singla, emphasized:
The core concept of CLEW nicotine pouch products is our unwavering commitment to providing consumers with an unparalleled experience by combining cutting-edge technology and the finest ingredients. CLEW nicotine pouches are developed in top laboratories in the United States, containing pharmaceutical-grade nicotine and carefully selected flavorings to ensure a satisfying experience with every use.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
